Shield Therapeutics plc Working Capital to Net Assets Ratio
Shield Therapeutics plc working capital to net assets ratio. Shield Therapeutics plc (STX) has a Working Capital to Net Assets ratio of 58.2% as of June 2025. Working capital of GBX-8.64 Million (current assets of GBX41.36 Million minus current liabilities of GBX50.01 Million) is measured against net assets of GBX-14.86 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible equity quality of Shield Therapeutics plc to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Shield Therapeutics plc (2013–2024)
Working capital to net assets ratio of Shield Therapeutics plc from 2013 to 2024. This chart shows how Shield Therapeutics plc's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2013 to 2024. As of June 2025, the ratio stands at 58.2%, reflecting working capital of GBX-8.64 Million against net assets of GBX-14.86 Million GBX. See Shield Therapeutics plc (STX) liquidity interval to measure how many days the company can operate on defensive assets alone.
Shield Therapeutics plc Working Capital to Net Assets Ratio by Year (2013–2024)
Shield Therapeutics plc working capital to net assets ratio by year from 2013 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Shield Therapeutics plc from 2013 to 2024, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Shield Therapeutics plc asset portfolio.
| Year | WC/NA Ratio | Working Capital (GBX) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -403.6% | GBX4.24 Million | GBX-1.05 Million | GBX30.29 Million | GBX26.05 Million | ▼ -495.5 pp |
| 2023 | 91.8% | GBX20.49 Million | GBX22.31 Million | GBX31.26 Million | GBX10.77 Million | ▲ +101.9 pp |
| 2022 | -10.0% | GBX-545.00K | GBX5.43 Million | GBX10.09 Million | GBX10.64 Million | ▼ -43.9 pp |
| 2021 | 33.8% | GBX13.88 Million | GBX41.03 Million | GBX17.26 Million | GBX3.38 Million | ▲ +24.0 pp |
| 2020 | 9.8% | GBX2.98 Million | GBX30.28 Million | GBX5.23 Million | GBX2.25 Million | ▲ +2.9 pp |
| 2019 | 6.9% | GBX2.22 Million | GBX32.15 Million | GBX6.39 Million | GBX4.17 Million | ▼ -16.5 pp |
| 2018 | 23.4% | GBX9.46 Million | GBX40.43 Million | GBX12.42 Million | GBX2.95 Million | ▼ -3.8 pp |
| 2017 | 27.3% | GBX11.23 Million | GBX41.21 Million | GBX15.00 Million | GBX3.76 Million | ▼ -12.8 pp |
| 2016 | 40.1% | GBX19.39 Million | GBX48.40 Million | GBX23.38 Million | GBX3.99 Million | ▲ +33.4 pp |
| 2015 | 6.7% | GBX-1.25 Million | GBX-18.64 Million | GBX2.33 Million | GBX3.58 Million | ▼ -39.5 pp |
| 2014 | 46.2% | GBX-8.45 Million | GBX-18.28 Million | GBX556.00K | GBX9.00 Million | ▼ -60.3 pp |
| 2013 | 106.5% | GBX-6.40 Million | GBX-6.00 Million | GBX1.65 Million | GBX8.05 Million | — |